Write a review
Reviews: 0
Manufacturers: Heber Biotec, SA
Active ingredients
- Sulfadiazine
Disease class
- Decubital ulcer
- Chronic skin ulcer, not elsewhere classified
- Presence of transplanted skin, autogenous skin graft
- Superficial trauma to an unspecified area of the body
- Post-traumatic wound infection, not elsewhere classified
- Thermal and chemical burns of unspecified localization
Clinical and pharmacological group
- Not indicated. See instructions
Pharmacological action
- Antimicrobial
- Antibacterial
Pharmacological group
- Regenerants and reparants
- Dermatotropic agents
Ointment for external use Ebermin
Instructions for medical use of the drug
Description of pharmacological action
Active against gram-positive and gram-negative microorganisms (including Pseudomonas aeruginosa, Escherichia coli, Proteus spp., Staphylococcus spp., Klebsiella spp.), fungi of the genus Candida (including Candida albicans) and dermatophytes. Upon contact with wound exudates, silver sulfadiazine slowly dissociates with the release of silver and sulfanilamide ions, the concentrations of which are sufficient to suppress the growth of pathogenic microorganisms and at the same time do not have a damaging effect on tissue cells. About 10% of sulfadiazine and 1% of silver are absorbed into the peripheral and systemic circulation. Application to large wound surfaces is accompanied by an increase in the concentration of sulfadiazine in the blood to 10–20 mcg/ml.
Indications for use
Infected superficial wounds and burns with weak exudation, trophic ulcers, bedsores, long-term non-healing ulcers (including stump wounds), abrasions, skin grafts.
Release form
ointment for external use; polyethylene bottle (bottle) 30 g cardboard pack 1; ointment for external use; polyethylene bottle (bottle) 200 g cardboard pack 1;
Pharmacodynamics
The combined drug has wound-healing and antiseptic properties. The active components are human epidermal growth factor (HEF) and silver sulfadiazine. EGF is a peptide containing 53 amino acids, obtained on the basis of recombinant DNA technology using a genetically modified yeast strain. Stimulates cell proliferation, accelerates epithelization of wounds (promotes the formation of a high-quality granulation zone). Silver sulfadiazine has an antimicrobial effect.
Pharmacokinetics
When the drug is applied to intact skin and burn wound surfaces, no resorption of EGF from the site of application into the systemic circulation is observed.
Use during pregnancy
Ebermin has not been sufficiently studied regarding the effects on the fetus or infants, therefore its use is not recommended during pregnancy and lactation. If a pregnant or breastfeeding woman has a lesion that can be treated with Ebermin, the doctor must determine the risk-benefit ratio and decide on its use.
Contraindications for use
Hypersensitivity to sulfonamides, pregnancy, lactation, children (up to 1 year). With caution. Liver and/or renal failure, glucose-6-phosphate dehydrogenase deficiency.
Side effects
Allergic reactions.
Directions for use and doses
Ebermin can be used at all stages of the wound process. Beforehand, standard surgical treatment of the wound is carried out using antiseptic solutions in case of infection. After drying, a layer of ointment of about 1-2 mm is applied to the wound surface. In the closed treatment method, sterile gauze pads or occlusive film coverings are placed on top (healing in a moist environment). In some cases, for example, with superficial shallow (I-II degree) and partially deep (III degree) burns, it is possible to use an ointment with atraumatic mesh wound coverings. With the wet healing method, as well as severe exudation, it is recommended to apply the ointment once a day. With moderate or scant exudation, the ointment can be applied once every 2 days. If the dressing sticks to the wound and to prevent unwanted drying of the wound surface, it is recommended to moisten the napkin applied over the ointment with a sterile 0.9% sodium chloride solution or antiseptic solutions. With the open (bandageless) method of treatment, the ointment is applied 1-3 times a day. Wash the wound before repeated applications of the ointment using a sterile 0.9% sodium chloride solution or antiseptic solutions. The procedure is performed carefully, avoiding injury to the resulting granulation tissue and growing epithelium when removing ointment residues. Treatment is continued until the wound is epithelialized or is ready for plastic closure with a skin flap. To prevent radiation dermatitis, a 1 mm layer of ointment is applied to the irradiated area of skin without removing it from the application site for 6-8 hours after irradiation. The use of the ointment is continued daily throughout the course of radiotherapy and is not interrupted in case of forced skipping of any of the radiation procedures.
Overdose
There have been no cases of overdose.
Interactions with other drugs
Compatible with systemic administration of other drugs (including antibiotics).
Special instructions for use
Use with caution in case of congenital deficiency of glucose-6-phosphate dehydrogenase, insufficiency of liver and kidney function. With the open (bandage-free) method of treatment, direct exposure to sunlight on the area where the ointment is applied should be avoided.
Storage conditions
At a temperature of 15 to 25 °C, protected from light and out of the reach of children.
Best before date
24 months
ATX classification:
D Dermatotropic drugs
D06 Antimicrobials for the treatment of skin diseases
D06B Other antimicrobials for external use
D06BA Sulfonamides
D06BA51 Silver sulfadiazine in combination with other drugs
pharmachologic effect
The drug contains recombinant epithelial growth factor (REGF), a peptide that has a stimulating effect, accelerating the division and migration of various types of cells, including fibroblasts, keratinocytes and endothelial cells.
Under the influence of the drug, scarring and wound healing are activated; The processes of restoring the elasticity of damaged tissues are more effective.
The mechanism of action of the recombinant epithelial growth factor included in the drug is fully consistent with the mechanism of action of endogenous (synthesized in the human body) refr.
Silver sulfadiazine, which is part of the ointment, has a pronounced antibacterial effect, destroying dermatophytes, some types of yeast fungi, and pathogenic bacteria.
The ointment is created on the basis of a hydrophilic base, which protects tissues from overdrying, dehydration, and promotes long-term preservation of therapeutic concentrations of active substances in the lesion.
According to patient reviews, Ebermin ointment has a noticeable cosmetic effect, accelerating the process of synthesis in the body of collagen fibers, making the skin texture more uniform. When using the ointment, the risk of formation of keloid scars that interfere with normal joint movement (formation of contractures) is reduced.
Pharmacokinetics
The use of the drug and its application to the surface of an open wound does not lead to the entry of active substances into the systemic bloodstream.
Composition of the drug:
- 100 g of Ebermin ointment contain:
- Active ingredients
- Recombinant epidermal growth factor - 1 mg
- Silver sulfadiazine - 1 g
- Excipients
- Glycerol - 5 g
- Potassium carbonate - 500 mg
- Methyl parahydroxybenzoate - 180 mg
- Propylhydroxybenzoate - 20 mg
- Stearic acid - 18 g
- Purified water - up to 100g
Scope of application
The ointment is used in the treatment of adults and children over 1 year of age. Indications for use are:
- Burns - superficial, deep.
- Bedsores.
- Trophic ulcers in erysipelas, obliterating endarteritis, diabetes mellitus, chronic venous insufficiency.
- Traumatic and surgical wounds, including wounds of the stump, wounds of donor sites after removal of skin flaps, wounds during surgical plastic surgery using skin flaps.
- Frostbite.
- Ulcerations on the skin surface associated with taking cytostatic drugs.
- Radiation dermatitis during radiation therapy.
Dosages and methods of use
Ebermin ointment is intended for local external use. Used in complex wound therapy at any stage of the wound process.
Before applying the ointment, wounds are routinely treated with antiseptic solutions to prevent infection. After treatment, the wound is dried and Ebermin is applied to its entire surface in a dense layer (1-2 mm).
Open method of therapy (without applying a bandage): the ointment is applied 1-3 times a day.
Closed method of therapy (with a bandage): the ointment is applied once a day for weeping wounds and once every 2 days with a minimal amount of exudate (discharge) or in its absence. A bandage of sterile gauze, film covering or mesh wound covering (for burn wounds) is applied over the ointment layer.
When the applied bandage dries to the surface of the wound, the bandage is moderately moistened with saline solution (sodium chloride solution) or antiseptic solution.
Before repeated applications of the ointment, the wound is treated with antiseptics - moderately, carefully, avoiding injury to the newly formed epithelial tissue.
Therapy with Ebermin ointment is carried out either until the wound is completely healed, or until it is prepared for surgical closure using a donor skin flap.
In the treatment and prevention of radiation dermatitis, Ebermin is applied as applications to the irradiated skin surface, leaving for 6-8 hours. Therapy is carried out daily throughout the course of treatment, including on days when the patient does not receive radiation therapy.
Side effects
According to reviews from patients and doctors, the use of Ebermin ointment in recommended doses does not cause unwanted side effects; the drug is well tolerated and does not have a systemic effect on the body.
In isolated cases, individual unfriendly reactions were observed - burning, a feeling of tightness, itching of the skin. As a rule, the discomfort goes away within 10-15 minutes after applying the bandage.
List of contraindications
- Allergic reaction to silver, sulfonamides
- Children's age up to 1 year
- Presence of active tumor formations in the area of the wound surface
- Wound therapy after surgical excision of a tumor
Ebermin is used with caution in the presence of liver or kidney failure, as well as congenital deficiency of glucose-6-phosphate dehydrogenase.
Pregnancy and lactation
The effect of the ointment on the fetus and on the health of breastfed children has not been studied.
The drug is not recommended for use during pregnancy and lactation.
In some cases, the doctor can determine the rationality of using Ebermin, taking into account the ratio of the benefits of the drug and the possible risks of its use.
special instructions
When choosing an open wound treatment method (without applying a fixing bandage), it is recommended to avoid exposure to the sun and exposure of the area where Ebermin is applied to sunlight.
Overdose
No cases of overdose have been recorded.
Interaction with other drugs
When using Ebermin, there have been no cases of incompatibility with other systemic or local drugs.
Shelf life
The shelf life of the drug is 24 months.
It is recommended to store Ebermin away from light, out of reach of children at a temperature of +15+25o.
Reviews about the drug
The high clinical effectiveness of the ointment is positively assessed by both doctors and patients.
The use of ointment significantly shortens the healing period of burns, ulcers, and wounds compared to other methods of therapy.
Ebermin's analogs
Ebermin is the only drug containing recombinant epidermal growth factor.
Important!
All information provided is provided for informational purposes and is not a guide for self-treatment.
Similar drugs:
- Furacilin Solution for topical use
- Lactobacterin siccum dry (Lactobacterin siccum) Lyophilisate for the preparation of solution for oral administration
- Palin Capsule
- Bactrim Oral suspension
- Nitroxoline Oral tablets
- Pancef Oral tablets
- Nifuroxazide (Nifuroxazide) Oral tablets
- Ercefuryl Oral suspension
- Sextaphag Oral solution
- Pancef Granules for the preparation of suspension for oral administration
** The Drug Directory is intended for informational purposes only. For more complete information, please refer to the manufacturer's instructions. Do not self-medicate; Before starting to use Ebermin, you should consult a doctor. EUROLAB is not responsible for the consequences caused by the use of information posted on the portal. Any information on the site does not replace medical advice and cannot serve as a guarantee of the positive effect of the drug.
Are you interested in the drug Ebermin? Do you want to know more detailed information or do you need a doctor's examination? Or do you need an inspection? You can make an appointment with a doctor - the Euro lab is always at your service! The best doctors will examine you, advise you, provide the necessary assistance and make a diagnosis. You can also call a doctor at home . Euro lab clinic is open for you around the clock.
** Attention! The information presented in this medication guide is intended for medical professionals and should not be used as a basis for self-medication. The description of the drug Ebermin is provided for informational purposes only and is not intended for prescribing treatment without the participation of a doctor. Patients need to consult a specialist!
If you are interested in any other drugs and medications, their descriptions and instructions for use, information about the composition and form of release, indications for use and side effects, methods of use, prices and reviews of drugs, or you have any other questions and suggestions - write to us, we will definitely try to help you.
